TPCW
AXSM icon

TD Private Client Wealth’s Axsome Therapeutics AXSM Stock Holding History

TD Private Client Wealth’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14
Closed -$1.63K – 1417
2025
Q1 		$1.63K Buy
+14
New +$1.59K ﹤0.01% 1220

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TD Private Client Wealth's AXSM Position: Q2 2025 in Review

TD Private Client Wealth sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 14 shares — an estimated $1.63K sold.

TD Private Client Wealth first reported a position in AXSM in Q1 2025 and held it in 1 quarter. The position peaked at $1.63K in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • TD Private Client Wealth reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • TD Private Client Wealth sold 14 Axsome Therapeutics shares in Q2 2025, an estimated $1.63K.
  • TD Private Client Wealth first reported a position in Axsome Therapeutics in Q1 2025 and held it in 1 quarter.
  • TD Private Client Wealth's Axsome Therapeutics position peaked at $1.63K in Q1 2025.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on TD Private Client Wealth's 13F filing for Q2 2025, filed 15 Jul 2025.